Search This Blog

Thursday, August 1, 2019

Blueprint Medicines EPS misses by $0.09, beats on revenue

Blueprint Medicines  (NASDAQ:BPMC): Q2 GAAP EPS of -$2.04 misses by $0.09.
Revenue of $5.11M (-87.7% Y/Y) beats by $3.72M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)